Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Similars in SciELO
Share
Cardiovascular and metabolic science
On-line version ISSN 2954-3835Print version ISSN 2683-2828
Abstract
RAMOS-MARTINEZ, Juan Carlos; HERNANDEZ-MERCADO, Marco Antonio; PEREZ-CAMPOS MAYORAL, Laura and RAMOS-MARTINEZ, Edgar Gustavo. Efficacy of treatment with evolocumab in patients with ischemic heart disease. Cardiovasc. metab. sci [online]. 2021, vol.32, n.2, pp.66-71. Epub Apr 05, 2024. ISSN 2954-3835. https://doi.org/10.35366/99743.
Introduction:
A new target level for low-density lipoprotein cholesterol (LDL-C) has been established in patients at very high cardiovascular risk. However, treatment with evolocumab combined with atorvastatin to attain this target level has not been evaluated.
Objective:
To evaluate the efficacy of evolocumab to achieve the target LDL-C levels in patients with ischemic heart disease at very high cardiovascular risk.
Material and methods:
Twenty patients with ischemic heart disease at very high cardiovascular risk were treated with evolocumab and atorvastatin for 24 weeks. Levels of serum LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol, and triglycerides were determined before and after treatment.
Results:
After 24 weeks of treatment, an average percentage reduction of 55% for LDL-C was obtained, and 11 of the 20 patients reached the target levels for LDL-C. No differences were found in the levels of HDL-C or triglycerides.
Conclusions:
evolocumab treatment was safe, effective, and reduced the concentration of LDL-C in all patients. However, the target level for LDL-C was only reached in half of the patients.
Keywords : Low density lipoprotein; PCSK9 inhibitor; evolocumab; ischemic heart disease; cholesterol.